Shareholder letter...
Shareholder letter...
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 14, 2024 • 4:05 EDT | Read More
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
Jun 27, 2024 • 9:15 EDT | Read More